About Neurodevelopmental Disorders
According to a survey published by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in 2012, children with suspected neurodevelopmental disorders such as ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) The percentage of children with neurodevelopmental disorders such as ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) is 6.5%. Patients with neurodevelopmental disorders are prone to various emotional and behavioral problems during adolescence and young adulthood, and early detection and intervention are needed to prevent secondary disorders and to broaden the scope of future social participation.
Challenges in Diagnosing Neurodevelopmental Disorders
The number of child psychiatry specialists and evaluators in the country has been shown to be overwhelmingly inadequate, with the following challenges
- Long period of time to consult a specialist and to be diagnosed. (It is especially difficult to receive appropriate medical care on remote islands or in areas where there are no specialized medical institutions.)
- There are limitations in collecting multifaceted information, and the absolute number of appropriately trained evaluators is insufficient throughout the country. As a result, they are forced to rely on simplified evaluation scales, which can easily lead to variations in severity assessment and diagnosis.
- Many children with neurodevelopmental disorders are withdrawn and have difficulty managing their time, so continuous attendance is not easy.
In Europe and the United States, remote evaluations are already being promoted in various medical fields, and videoconferencing is also used in psychiatry, but there are very few precedents for this in Japan.
Outline and Purpose of this Study
This study will be conducted by Dr. Taishiro Kishimoto, a full-time lecturer in the Department of Psychiatry and Neuroscience at Keio University School of Medicine, who is conducting research in the field of psychiatry using online medical services in Japan to introduce remote diagnosis and evaluation as a solution to these issues.
In order to demonstrate the usefulness of remote assessment in Japan, this study aims to conduct one remote and one face-to-face assessment by a physician or clinical psychologist with children with ASD and ADHD and their parents, and to verify whether the remote assessment is equivalent to the face-to-face assessment and whether the remote assessment is acceptable to the subjects. The purpose is to verify whether the remote evaluation is equivalent to the face-to-face evaluation and whether the remote evaluation is acceptable to the subject. In the future, we aim to improve the accessibility of medical care in the field of neurodevelopmental disorders by homogenizing diagnostic results through the implementation of central evaluation by professional evaluators in Japan.
This research was conducted under the "Program on Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA)" of the Japan Science and Technology Agency (JST). The research area "Creation of life innovation by PeOPLe, a platform for openly utilizing all kinds of information based on people" (Area Representative: Hiroaki Miyata, Professor, Department of Medical Policy and Management, Faculty of Medicine, Keio University; Leader: Tonomachi Advanced Research and Education Collaboration Square), in which Keio University is the lead institution in the "Program on Open Innovation Platform with Enterprises, Research Institute and Academia (OPERA)" of the Japan Science and Technology Agency (JST), is being conducted by the JST and MIC. The project is supported by JST and MICIN within the framework of "Creating Life Innovations with PeOPLe," an infrastructure for medical policy and management, Faculty of Medicine, Keio University.
Also participating in the examination will be the Shimada Rehabilitation Center of the Japan Society for Mentally and Physically Handicapped Children (located in Tama City, Tokyo) and the Tokyo Metropolitan Children's General Medical Center (located in Fuchu City, Tokyo).
In this study, MICIN will provide the online medical treatment system "CURON" for the remote severity assessment performed in the study. Although the online medical examination system is not a "medical device" for diagnosis or treatment, the quality of communication affects the accuracy of the evaluation, and is also important from the perspective of preventing information leakage since it handles medical information. Cron implements the confidentiality, network security, and unauthorized access measures that are essential for the proper implementation of online medical services, and is compliant with the three ministries and three guidelines already in use in the medical field.
About Cron Online Medical Service
Cron" is a service that completes everything online, from making appointments to medical interviews, consultations, payments, and delivery of medications and prescriptions. The service is supported by the fact that the cost burden on medical institutions for installation and operation is zero, and that doctors and patients can share data such as blood glucose levels and blood pressure.
Kron's service introduction site:.https://curon.co
About MICIN Corporation
MICIN is a company founded in 2015 with an application business that handles the online medical treatment service "CURON". In addition to being Japan's leading company in online medical services, MICIN is also developing various services for the healthcare field, including a data solution business that uses AI to analyze and utilize medical data, and a digital solution business (MiROHA) for clinical development of pharmaceuticals, in order to achieve its VISION of "a world where all people can live and die with dignity and satisfaction. The company is developing various services for the healthcare field, including a data solution business that analyzes and utilizes AI for medical data, and a digital solution business for clinical development of pharmaceuticals (MiROHA).
As for MICIN's future development, the knowledge gained from this study in assessing severity of illness using the video call function will be utilized in MICIN's "MiROHA" digital solution for clinical development. MICIN plans to deepen its support for scientific evidence building in Japan by providing an environment in which various verifications using the video call function can be conducted in the areas of clinical trials and research.
| name of company | MICIN Corporation |
| Establishment | November 26, 2015 |
| Location | 〒100-0004 13F, Nihon Bldg., 2-6-2 Otemachi, Chiyoda-ku, Tokyo |
| representative | Name of Representative Seigo Hara, Representative Director |
| Business Overview | Application business for medical institutions such as online medical services Data solution business that analyzes and utilizes medical data with AI, etc. Digital solution business for clinical development of pharmaceutical products |
| uniform resouce locator | https://micin.jp/ |








